Oxford Immunotec

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The T-SPOT.CMV test and the T-SPOT.PRT test are the Company's second and third products and part of a series of products intended for the transplantation market. In addition to these three products, the Company has an additional six active development programs, each of which leverages our T cell, B cell and innate immune measuring technology. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.
Company Growth (employees)
Type
Public
HQ
Milton, GB
Founded
2001
Size (employees)
431 (est)
Oxford Immunotec was founded in 2001 and is headquartered in Milton, GB

Key People at Oxford Immunotec

Peter Wrighton-Smith

Peter Wrighton-Smith

CEO
Richard M. Altieri

Richard M. Altieri

CFO

Oxford Immunotec Office Locations

Oxford Immunotec has offices in Milton, Kohoku Ward, Marlborough and Shanghai
Milton, GB (HQ)
115D Innovation Drive Milton Park Abingdon Oxfordshire
Shanghai, CN
1701, Tower 2, Shanghai Arch Hongqiao, 533 Loushanguang Road
Marlborough, US
200 700 Nickerson Rd
Kohoku Ward, JP
8F Nisso Bldg. No16, 3-8-8 Shinyokohama

Oxford Immunotec Data and Metrics

Oxford Immunotec Financial Metrics

Oxford Immunotec's revenue was reported to be £46.4 m in FY, 2015 which is a 27% increase from the previous period.
GBP

Revenue (FY, 2015)

46.4 m

Revenue growth (FY, 2014 - FY, 2015), %

27%

Gross profit (FY, 2015)

24.6 m

Gross profit margin (FY, 2015), %

53%

Net income (FY, 2015)

(18.1 m)

Market capitalization (19-Sep-2017)

363.9 m

Closing share price (19-Sep-2017)

15.7

Cash (31-Dec-2015)

62 m
Oxford Immunotec's current market capitalization is $363.9 m.
GBPFY, 2013FY, 2014FY, 2015

Revenue

25.5 m36.6 m46.4 m

Revenue growth, %

44%27%

Cost of goods sold

12.2 m17.8 m21.8 m

Gross profit

13.3 m18.9 m24.6 m
GBPFY, 2013FY, 2014FY, 2015

Cash

50.6 m37.4 m62 m

Accounts Receivable

3.1 m5 m5.2 m

Current Assets

58.8 m49.2 m75.1 m

PP&E

1.9 m3.4 m4.6 m
GBPFY, 2013FY, 2014FY, 2015

Cash From Operating Activities

(3.7 m)(15.4 m)(12.2 m)

Cash From Financing Activities

46.5 m(111.7 k)39.7 m

Income Taxes Paid

(60.5 k)(113.9 k)(108 k)
GBPY, 2015

Revenue/Employee

193.7 k

Financial Leverage

1.2 x
Show all financial metrics

Oxford Immunotec Market Value History

Traffic Overview of Oxford Immunotec

Oxford Immunotec Online and Social Media Presence

Oxford Immunotec Company Life and Culture

You may also be interested in